Latest Arch Therapeutics Inc. (ARTH) Headlines
Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 8:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, MD, is scheduled to present a corporate overview at The Wall Street Analyst Forum Conference in Manhattan at The University Club of NYC on Monday, March 3rd at 12:05 PM EST.
10-Q: ARCH THERAPEUTICS, INC.
Edgar Online - Fri Feb 14, 7:42AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Arch Therapeutics Secures $2.85 Million Private Placement
Marketwire - Mon Feb 10, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care has closed a previously announced private placement to accredited individual and institutional investors (the "Investors").
OTC Daily Alert Stock Watch - Arch Therapeutics, Inc. (OTCQB: ARTH)
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Arch Therapeutics Announces $2.85 Million Private Placement
Marketwire - Fri Jan 31, 5:00AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce today its private placement to institutional and high net worth investors of an aggregate of 11,400,000 shares of common stock at $0.25 per share, pursuant to the terms of a securities purchase agreement dated January 30, 2014. The private placement is expected to close on or about February 4, 2014, subject to customary closing conditions.
Arch Therapeutics Presents 2014 Milestones During Live Webcast
Marketwire - Wed Jan 22, 10:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., presented its calendar year 2014 milestone targets during a live audio and high-definition video webcast on Wednesday, January 22 at 10:30AM Eastern Time from the Noble Financial Capital Markets' Tenth Annual Equity Conference in South Florida.
Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity Conference
Marketwire - Tue Jan 14, 8:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference in Sandpiper Bay, Florida, on Wednesday, January 22 at 10:30AM Eastern Time.
Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference
Marketwire - Wed Jan 08, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Terrence W. Norchi, M.D., CEO of Arch Therapeutics will present at The Biotech Showcase(TM) 2014 conference on Monday, January 13th, at 5:00PM PST. Attendees will find the presentation scheduled for "Track C" in the Mission II room at that time. Dr. Norchi's presentation will provide insights into the Company's ongoing activities to commercially develop novel technologies into a suite of new products targeting markets of unmet clinical need.
Arch Therapeutics Co-Founder Dr. Ellis-Behnke to Speak at Nanomanufacturing Summit 2013 in Philadelphia, October 15, 2013
Marketwire - Thu Oct 10, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), is pleased to announce that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, will be featured during the opening day activities at the Nanomanufacturing Summit 2013 October 15-17, 2013 at the University of Pennsylvania in Philadelphia.
Arch Therapeutics Announces Approval of $1 Million Massachusetts Life Sciences Center Accelerator Loan
Marketwire - Mon Oct 07, 8:02AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that the Massachusetts Life Sciences Center (the "Center"), a quasi-public agency tasked with implementing the state's $1 billion Life Sciences Initiative, has concluded the requisite steps to award Arch with a $1 million dollar Accelerator Loan.
Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27
Marketwire - Fri Sep 20, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the Boulder Peptide Symposium 2013. The conference is being held September 25-27, 2013, at the St Julien Hotel in Boulder, Colorado.
Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
Marketwire - Tue Sep 03, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference. The conference, sponsored by H.C. Wainwright & Co., LLC, is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
Arch Therapeutics Announces Plans for Upcoming Activities
Marketwire - Tue Aug 06, 2:06PM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to provide a brief review of proposed future activities.
Arch Therapeutics Reports on Current Activities
Marketwire - Tue Jul 30, 8:02AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to provide a summary of current events.
OTC Daily Alert Stock Watch
WorldStockWire - Thu Jul 25, 1:46AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Arch Therapeutics Co-Founder Dr. Ellis-Behnke Speaks at 6th Annual CLINAM Nanomedicine Summit in Basel, Switzerland
Marketwire - Tue Jul 23, 8:51AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to advise that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a lecture titled "The Spider Effect, how the Immune System in the Brain can be Measured and Modulated with Nanotechnology" at the 6th annual European Foundation for Clinical Nanomedicine (CLINAM) Summit in Basel, Switzerland.
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu, Greece
Marketwire - Tue Jul 16, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to advise that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a keynote lecture titled "Translating Nanomedicine: Molecular medical devices from Nano Neuro Knitting to Immediate Hemostasis to Cancer Stem Cell Arrest" in Corfu, Greece at the Technology Transfer Workshop: From the Lab to the Marketplace.
ARTH, XUII, AAMRQ and SCRC added to OTC Active Stock Watch List at GSR
ACCESSWIRE - Tue Jul 16, 8:01AM CDT
New York, NY - (ACCESSWIRE) - 07/16/2013 - Growing Stock Report initiates its OTC Active Stock Watch List adding Arch Therapeutics, Inc. (OTC:ARTH), Xumanii (OTC:XUII), AMR Corporation (OTC:AAMRQ) and ScripsAmerica, Inc. (OTC:SCRC)
BIZM, ARTH, AAMRQ and SGLB added to Active OTC Watch List at EPR
ACCESSWIRE - Thu Jul 11, 8:06AM CDT
New York, NY - (ACCESSWIRE) - (07/11/2013) - Equity Profile Report initiates an Active OTC Watch List adding Biozoom, Inc. (OTC:BIZM), Arch Therapeutics, Inc. (OTC:ARTH), AMR Corporation (OTC:AAMRQ) and Sigma Labs, Inc. (OTC:SGLB).
Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 8:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, MD, is scheduled to present a corporate overview at The Wall Street Analyst Forum Conference in Manhattan at The University Club of NYC on Monday, March 3rd at 12:05 PM EST.
10-Q: ARCH THERAPEUTICS, INC.
Edgar Online - Fri Feb 14, 7:42AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Arch Therapeutics Secures $2.85 Million Private Placement
Marketwire - Mon Feb 10, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care has closed a previously announced private placement to accredited individual and institutional investors (the "Investors").
OTC Daily Alert Stock Watch - Arch Therapeutics, Inc. (OTCQB: ARTH)
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Arch Therapeutics Announces $2.85 Million Private Placement
Marketwire - Fri Jan 31, 5:00AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce today its private placement to institutional and high net worth investors of an aggregate of 11,400,000 shares of common stock at $0.25 per share, pursuant to the terms of a securities purchase agreement dated January 30, 2014. The private placement is expected to close on or about February 4, 2014, subject to customary closing conditions.
Arch Therapeutics Presents 2014 Milestones During Live Webcast
Marketwire - Wed Jan 22, 10:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., presented its calendar year 2014 milestone targets during a live audio and high-definition video webcast on Wednesday, January 22 at 10:30AM Eastern Time from the Noble Financial Capital Markets' Tenth Annual Equity Conference in South Florida.
Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity Conference
Marketwire - Tue Jan 14, 8:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference in Sandpiper Bay, Florida, on Wednesday, January 22 at 10:30AM Eastern Time.
Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference
Marketwire - Wed Jan 08, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Terrence W. Norchi, M.D., CEO of Arch Therapeutics will present at The Biotech Showcase(TM) 2014 conference on Monday, January 13th, at 5:00PM PST. Attendees will find the presentation scheduled for "Track C" in the Mission II room at that time. Dr. Norchi's presentation will provide insights into the Company's ongoing activities to commercially develop novel technologies into a suite of new products targeting markets of unmet clinical need.
Arch Therapeutics Co-Founder Dr. Ellis-Behnke to Speak at Nanomanufacturing Summit 2013 in Philadelphia, October 15, 2013
Marketwire - Thu Oct 10, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), is pleased to announce that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, will be featured during the opening day activities at the Nanomanufacturing Summit 2013 October 15-17, 2013 at the University of Pennsylvania in Philadelphia.
Arch Therapeutics Announces Approval of $1 Million Massachusetts Life Sciences Center Accelerator Loan
Marketwire - Mon Oct 07, 8:02AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that the Massachusetts Life Sciences Center (the "Center"), a quasi-public agency tasked with implementing the state's $1 billion Life Sciences Initiative, has concluded the requisite steps to award Arch with a $1 million dollar Accelerator Loan.
Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27
Marketwire - Fri Sep 20, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the Boulder Peptide Symposium 2013. The conference is being held September 25-27, 2013, at the St Julien Hotel in Boulder, Colorado.
Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
Marketwire - Tue Sep 03, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference. The conference, sponsored by H.C. Wainwright & Co., LLC, is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
Arch Therapeutics Announces Plans for Upcoming Activities
Marketwire - Tue Aug 06, 2:06PM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to provide a brief review of proposed future activities.
Arch Therapeutics Reports on Current Activities
Marketwire - Tue Jul 30, 8:02AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to provide a summary of current events.
OTC Daily Alert Stock Watch
WorldStockWire - Thu Jul 25, 1:46AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Arch Therapeutics Co-Founder Dr. Ellis-Behnke Speaks at 6th Annual CLINAM Nanomedicine Summit in Basel, Switzerland
Marketwire - Tue Jul 23, 8:51AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to advise that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a lecture titled "The Spider Effect, how the Immune System in the Brain can be Measured and Modulated with Nanotechnology" at the 6th annual European Foundation for Clinical Nanomedicine (CLINAM) Summit in Basel, Switzerland.
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu, Greece
Marketwire - Tue Jul 16, 8:01AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to advise that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a keynote lecture titled "Translating Nanomedicine: Molecular medical devices from Nano Neuro Knitting to Immediate Hemostasis to Cancer Stem Cell Arrest" in Corfu, Greece at the Technology Transfer Workshop: From the Lab to the Marketplace.
ARTH, XUII, AAMRQ and SCRC added to OTC Active Stock Watch List at GSR
ACCESSWIRE - Tue Jul 16, 8:01AM CDT
New York, NY - (ACCESSWIRE) - 07/16/2013 - Growing Stock Report initiates its OTC Active Stock Watch List adding Arch Therapeutics, Inc. (OTC:ARTH), Xumanii (OTC:XUII), AMR Corporation (OTC:AAMRQ) and ScripsAmerica, Inc. (OTC:SCRC)
BIZM, ARTH, AAMRQ and SGLB added to Active OTC Watch List at EPR
ACCESSWIRE - Thu Jul 11, 8:06AM CDT
New York, NY - (ACCESSWIRE) - (07/11/2013) - Equity Profile Report initiates an Active OTC Watch List adding Biozoom, Inc. (OTC:BIZM), Arch Therapeutics, Inc. (OTC:ARTH), AMR Corporation (OTC:AAMRQ) and Sigma Labs, Inc. (OTC:SGLB).
